Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...

DUBLIN--(BUSINESS WIRE)--The "RNA-interference (RNAi) Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The RNA-interference (RNAi) ...

The red-hot field of RNA interference (RNAi) could benefit from patents issued jointly to Queensland, Australia-based Benitec, and the State of Queensland (US patent 6,573,099, issued June 3, 2003, ...

Coronavirus disease 2019 (COVID-19) vaccines have played a critical role in reducing transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission. However, with ...

In drug discovery, very little of what’s learned from one project can typically be carried over to the next. “For every new target you go after with a small molecule, you basically start from scratch, ...

Getting siRNA into the Right Place in the Cell Might Not Be a Problem for Much Longer For about five years now, pharmaceutical companies have been interested in developing therapeutics based on the ...

Researchers Tout Delivery Strategies that Have the Potential to Get New Drugs into Trials Sooner As more of the human genome is identified and characterized, new frontiers open for therapeutics. “The ...

RNA interference (RNAi) is a key biological process that leads to the silencing of gene expression. RNAi can be initiated by a cell in response to pathogenic nucleic acids to bring about a targeted ...

Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...

– Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA and First and Only to Treat Hemophilia A or B With or Without Inhibitors – Qfitlia is the sixth Alnylam-discovered ...